#United States #New York #Class Action #Investor Rights #Cytokinetics

Join the Class Action Suit Against Cytokinetics

Deadline Approaching: December 27, 2023 to May 6, 2025

Are you a shareholder of Cytokinetics, Incorporated (NASDAQ: CYTK)? If so, The Gross Law Firm is reaching out to you with an important opportunity. Shareholders who acquired shares during the period between December 27, 2023, and May 6, 2025, are encouraged to join a class action lawsuit related to the company's business practices. The filing deadline to participate as a lead plaintiff is set for November 17, 2025, and it is crucial that you act promptly to protect your interests.

The Allegations: The lawsuit centers on claims that Cytokinetics misled shareholders with false and misleading statements about the approval process for its New Drug Application (NDA) for aficamten. Specifically, the company claimed it expected FDA approval in the latter half of 2025, based on an anticipated PDUFA date of September 26, 2025. However, they failed to disclose significant risks tied to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could potentially delay the regulatory process.

On May 6, 2025, it was revealed during an earnings call that Cytokinetics had engaged in multiple pre-NDA meetings with the FDA regarding safety monitoring but nevertheless chose to proceed with their NDA submission without a REMS. This decision pointed to a reckless oversight that misled investors about the true status of the regulatory timeline affecting the drug.

As a result of these misleading statements, investors purchased shares of Cytokinetics at inflated prices, and significant losses ensued once the true details were disclosed. This has prompted The Gross Law Firm to act on behalf of these affected shareholders.

Next Steps for Interested Shareholders: If you bought shares of Cytokinetics in the designated timeframe, registering for this class action lawsuit will allow you to enlist in a portfolio monitoring service that keeps you updated throughout the process. Notably, the lead plaintiff role does not require any obligation to join the lawsuit, yet acting quickly is critical.

Why Choose The Gross Law Firm?: Renowned nationally for its class action expertise, The Gross Law Firm dedicates itself to upholding the rights of investors defrauded through corporate misconduct. The firm firmly believes in ensuring that companies like Cytokinetics adhere to ethical business practices and respect their obligations to shareholders.

Take this opportunity to stand up for your rights as an investor. Time is of the essence – contact The Gross Law Firm today through the provided link to initiate your registration in the class action. You can find more information and register via this link. The deadline is rapidly approaching, and participation is free.

Contact Information:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Phone: (646) 453-8903
Email: [email protected]